KFAR-SABA, ISRAEL & ALISO VIEJO, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/cathworks?src=hash” target=”_blank”gt;#cathworkslt;/agt;–CathWorks announced that Mike Feher has joined CathWorks as Vice
President of Finance and Chief Financial Officer. His appointment
coincides with US commercialization of the CathWorks FFRangio™ System.
Mr. Feher will initially focus on the development of financial and
operational capabilities, as well as creating value for the organization
through the execution of company’s strategy.
Mike joins CathWorks with over 13 years of finance and strategy
experience in companies such as Edwards Lifesciences, Volcom and
Deloitte. That experience includes deep understanding of investor
relationships, strategic planning and financial operations. Mike is a
certified public accountant. He earned his B.S. in Accounting, Finance
and Economics from Chapman University and his MBA from University of
Jim Corbett, CathWorks CEO, said of Mike’s appointment, “I am very
excited to have Mike join our leadership team. Mike’s strategic mindset
and broad financial acumen will be a significant addition to our team.
The CathWorks System represents a tremendous opportunity for
interventional cardiologists to improve the quality of care and lower
costs in the treatment of multi-vessel coronary artery disease. I am
confident in Mike’s ability to lead our finance organization as we
continue to work towards achieving our strategic plan.”
Mr. Feher said, “I am excited about joining CathWorks and its dynamic
leadership team. We look forward to the US commercialization of the
CathWorks FFRangio in the next few weeks and cannot wait to
see the impact of this transformational technology on patients,
physicians, and health systems.”
The CathWorks FFRangio System quickly and precisely delivers
the objective FFR guidance needed to optimize PCI therapy decisions for
every patient. It is non-invasive and performed intra-procedurally
during coronary angiography without adding additional clinical risk or
per-procedure costs. The company received U.S. FDA 510(k) clearance for
the CathWorks FFRangioCoronary Vascular
Physiologic Simulation Software on December 19, 2018.
CathWorks is a medical technology company focused on applying its
advanced computational science platform to optimize PCI therapy
decisions and elevate coronary angiography from visual assessment to an
objective FFRangio based decision-making tool for physicians.
FFR-guided PCI decision-making is proven to provide significant clinical
benefits for patients with coronary artery disease and economic benefits
for patients and payers. The company’s focus is specifically on bringing
the CathWorks FFRangio System to market to provide quick,
precise, and objective intraprocedural FFRangio guidance that
is practical for every case.